Table 1.
Characteristics of the Study Population.
| Immunized |
COVID-19 Positive | ||||
|---|---|---|---|---|---|
| Healthy | Cancer | IST | |||
| n = 210 | n = 42 | n = 44 | n = 42 | n = 82 | |
| Age, median (range) | 64 (12–93) |
57 (19–80) | 66 (40–92) | 61 (18–83) | 65 (12–93) |
| Sex | |||||
| Male (%) | 92 (43.8) | 18 (42.9) | 16 (36.4) | 20 (47.6) | 38 (46.3) |
| Female (%) | 118 (56.2) | 24 (57.1) | 28 (63.6) | 22 (52.4) | 44 (53.7) |
| Quantitative Samples, median (range) | |||||
| Euroimmun (BAU/mL) | 390.5 (3.2–67,910) | 505 (14.1–10,448) | 157 (3.2–11,442) | 160 (3.2–7,040) | 1,044 (3.2–67,910) |
| Abbott (BAU/mL) | 172.8 (3.1–35268.1) | 167.8 (3.1–6,128.4) | 129.5 (3.1–6,816.4) | 75.1 (3.1–6,792.4) | 848.0 (3.1–35268.1) |
| Roche (BAU/mL) | 241 (0.4–257,160) | 335 (1.99–50,573) | 240 (0.4–36,052) | 371 (0.4–42,005) | 212 (0.4–257,160) |
| DiaSorin (BAU/mL) | 623 (4.8–86,100) | 865 (6.98–26,600) | 364 (4.8–21,200) | 175 (4.8–14,000) | 1,065 (4.8–86,100) |